A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype.
John F MarcellettiBranimir I SikicPublished in: Cancer chemotherapy and pharmacology (2023)
NCT00233909; First posted October 06, 2005.